Silodosin: Pharmacological and clinical features

Frank Strittmatter, Petter Hedlund

Research output: Contribution to journalArticle

Abstract

Benign prostatic hyperplasia is one of the most common diseases of elderly men and is often, but not exclusively, associated with lower urinary tract symptoms. The primary aim of therapy is to improve lower urinary tract symptoms and quality of life and, second, to prevent complications, such as urinary retention, upper urinary tract dilatation and infection. α 1- blockers are used as first-line therapy. Today, there are different α-blockers available. They have comparable clinical effectiveness; however, they differ in their tolerability profiles. The α 1A- receptor selectivity may be one reason for the difference in the tolerability profile. A new very selective α 1A-blocker, named silodosin, is now available in Europe. This article gives an overview of the chemical structure of silodosin, its pharmacokinetics, metabolism, interaction with other drugs and pharmacodynamics. In the second half of this article, the clinical efficacy of silodosin and its adverse events are highlighted and compared with other available α 1-blockers.

Original languageEnglish
Pages (from-to)45-57
Number of pages13
JournalAging Health
Volume7
Issue number1
DOIs
Publication statusPublished - Feb 2011

Fingerprint

Lower Urinary Tract Symptoms
Pharmacology
Urinary Retention
Prostatic Hyperplasia
Urinary Tract Infections
Dilatation
Pharmacokinetics
Quality of Life
Therapeutics
Pharmaceutical Preparations
silodosin

Keywords

  • Β-adrenoceptor antagonist
  • benign prostatic hyperplasia
  • bladder outlet obstruction
  • lower urinary tract symptoms
  • silodosin
  • smooth muscle contraction

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

Silodosin : Pharmacological and clinical features. / Strittmatter, Frank; Hedlund, Petter.

In: Aging Health, Vol. 7, No. 1, 02.2011, p. 45-57.

Research output: Contribution to journalArticle

Strittmatter, F & Hedlund, P 2011, 'Silodosin: Pharmacological and clinical features', Aging Health, vol. 7, no. 1, pp. 45-57. https://doi.org/10.2217/ahe.10.81
Strittmatter, Frank ; Hedlund, Petter. / Silodosin : Pharmacological and clinical features. In: Aging Health. 2011 ; Vol. 7, No. 1. pp. 45-57.
@article{df173db37fee45358c9946320d38632e,
title = "Silodosin: Pharmacological and clinical features",
abstract = "Benign prostatic hyperplasia is one of the most common diseases of elderly men and is often, but not exclusively, associated with lower urinary tract symptoms. The primary aim of therapy is to improve lower urinary tract symptoms and quality of life and, second, to prevent complications, such as urinary retention, upper urinary tract dilatation and infection. α 1- blockers are used as first-line therapy. Today, there are different α-blockers available. They have comparable clinical effectiveness; however, they differ in their tolerability profiles. The α 1A- receptor selectivity may be one reason for the difference in the tolerability profile. A new very selective α 1A-blocker, named silodosin, is now available in Europe. This article gives an overview of the chemical structure of silodosin, its pharmacokinetics, metabolism, interaction with other drugs and pharmacodynamics. In the second half of this article, the clinical efficacy of silodosin and its adverse events are highlighted and compared with other available α 1-blockers.",
keywords = "Β-adrenoceptor antagonist, benign prostatic hyperplasia, bladder outlet obstruction, lower urinary tract symptoms, silodosin, smooth muscle contraction",
author = "Frank Strittmatter and Petter Hedlund",
year = "2011",
month = "2",
doi = "10.2217/ahe.10.81",
language = "English",
volume = "7",
pages = "45--57",
journal = "Aging Health",
issn = "1745-509X",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Silodosin

T2 - Pharmacological and clinical features

AU - Strittmatter, Frank

AU - Hedlund, Petter

PY - 2011/2

Y1 - 2011/2

N2 - Benign prostatic hyperplasia is one of the most common diseases of elderly men and is often, but not exclusively, associated with lower urinary tract symptoms. The primary aim of therapy is to improve lower urinary tract symptoms and quality of life and, second, to prevent complications, such as urinary retention, upper urinary tract dilatation and infection. α 1- blockers are used as first-line therapy. Today, there are different α-blockers available. They have comparable clinical effectiveness; however, they differ in their tolerability profiles. The α 1A- receptor selectivity may be one reason for the difference in the tolerability profile. A new very selective α 1A-blocker, named silodosin, is now available in Europe. This article gives an overview of the chemical structure of silodosin, its pharmacokinetics, metabolism, interaction with other drugs and pharmacodynamics. In the second half of this article, the clinical efficacy of silodosin and its adverse events are highlighted and compared with other available α 1-blockers.

AB - Benign prostatic hyperplasia is one of the most common diseases of elderly men and is often, but not exclusively, associated with lower urinary tract symptoms. The primary aim of therapy is to improve lower urinary tract symptoms and quality of life and, second, to prevent complications, such as urinary retention, upper urinary tract dilatation and infection. α 1- blockers are used as first-line therapy. Today, there are different α-blockers available. They have comparable clinical effectiveness; however, they differ in their tolerability profiles. The α 1A- receptor selectivity may be one reason for the difference in the tolerability profile. A new very selective α 1A-blocker, named silodosin, is now available in Europe. This article gives an overview of the chemical structure of silodosin, its pharmacokinetics, metabolism, interaction with other drugs and pharmacodynamics. In the second half of this article, the clinical efficacy of silodosin and its adverse events are highlighted and compared with other available α 1-blockers.

KW - Β-adrenoceptor antagonist

KW - benign prostatic hyperplasia

KW - bladder outlet obstruction

KW - lower urinary tract symptoms

KW - silodosin

KW - smooth muscle contraction

UR - http://www.scopus.com/inward/record.url?scp=79951741587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951741587&partnerID=8YFLogxK

U2 - 10.2217/ahe.10.81

DO - 10.2217/ahe.10.81

M3 - Article

AN - SCOPUS:79951741587

VL - 7

SP - 45

EP - 57

JO - Aging Health

JF - Aging Health

SN - 1745-509X

IS - 1

ER -